New drug duo shows promise for tough lymphoma cases
NCT ID NCT05267054
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This study tested a new drug (ociperlimab) combined with either tislelizumab or rituximab in 53 people whose diffuse large B-cell lymphoma had come back or stopped responding to treatment. The main goals were to check safety and find the best dose. Researchers also looked at whether the tumors shrank. This is an early-stage trial, so it focuses on safety and dosing, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, 200032, China
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, 100050, China
-
Beijing Hospital
Beijing, Beijing Municipality, 100730, China
-
Guangdong Provincial Peoples Hospital
Guangzhou, Guangdong, 510080, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Jiangxi Province Cancer Hospital
Nanchang, Jiangxi, 330029, China
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
-
Shengjing Hospital of China Medical University
Shenyang, Liaoning, 110004, China
-
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
Chengdu, Sichuan, 610071, China
-
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310016, China
-
Sun Yat Sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Nanchang University Branch Donghu
Nanchang, Jiangxi, 330006, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
-
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
-
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.